JOHANNESBURG - A new Alzheimer’s drug is expected to be approved by the US Food and Drug Administration after a positive clinical trial.
It confirmed that the drug, donanemab, slows cognitive decline in patients with early stages of the disease.
The drug showed a 35-percent slowdown in patients with mild disease, but the benefit was less apparent in advanced cases.
Wits Emeritus Professor of Neurology and Neurosciences, Girish Modi, says it's exciting news.
"This one is particularly exciting because of the 35-percent reductio or slowing down of cognitive decline. We've never had something like this," he said.